The utility of next-generation sequencing technologies in diagnosis of Mendelian mitochondrial diseases and reflections on clinical spectrum
Authors:
- 24 February 2021
- journal article
- research article
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 34 (4) , 417-430
Abstract
Objectives Diagnostic process of mitochondrial disorders (MD) is challenging because of the clinical variability and genetic heterogeneity of these conditions. Next-Generation Sequencing (NGS) technology offers a high-throughput platform for nuclear MD. Methods We included 59 of 72 patients that undergone WES and targeted exome sequencing panel suspected to have potential PMDs. Patients who were included in the analysis considering the possible PMD were reviewed retrospectively and scored according to the Mitochondrial Disease Criteria Scale. Results Sixty-one percent of the patients were diagnosed with whole-exome sequencing (WES) (36/59) and 15% with targeted exome sequencing (TES) (9/59). Patients with MD-related gene defects were included in the mito group, patients without MD-related gene defects were included in the nonmito group, and patients in whom no etiological cause could be identified were included in the unknown etiology group. In 11 out of 36 patients diagnosed with WES, a TES panel was applied prior to WES. In 47 probands in 39 genes ( SURF1, SDHAF1, MTO1, FBXL4, SLC25A12, GLRX5, C19oRF12, NDUFAF6, DARS2, BOLA3, SLC19A3, SCO1, HIBCH, PDHA1, PDHAX, PC, ETFA, TRMU, TUFM, NDUFS6, WWOX, UBCD TREX1, ATL1, VAC14, GFAP, PLA2G6, TPRKB, ATP8A2, PEX13, IGHMBP2, LAMB2, LPIN1, GFPT1, CLN5, DOLK ) (20 mito group, 19 nonmito group) 59 variants (31 mito group, 18 nonmito group) were detected. Seven novel variants in the mito group ( SLC25A12, GLRX5, DARS2, SCO1, PC, ETFA, NDUFS6 ), nine novel variants in the nonmito group ( IVD, GCDH, COG4, VAC14, GFAP, PLA2G6, ATP8A2, PEX13, LPIN1 ) were detected. Conclusions We explored the feasibility of identifying pathogenic alleles using WES and TES in MD. Our results show that WES is the primary method of choice in the diagnosis of MD until at least all genes responsible for PMD are found and are highly effective in facilitating the diagnosis process.Keywords
This publication has 41 references indexed in Scilit:
- Mutations in FBXL4, Encoding a Mitochondrial Protein, Cause Early-Onset Mitochondrial EncephalomyopathyThe American Journal of Human Genetics, 2013
- Next generation molecular diagnosis of mitochondrial disordersMitochondrion, 2013
- Barth syndromeOrphanet Journal of Rare Diseases, 2013
- Next‐generation sequencing for mitochondrial diseases: A wide diagnostic spectrumPediatrics International, 2012
- Molecular Diagnosis of Infantile Mitochondrial Disease with Targeted Next-Generation SequencingScience Translational Medicine, 2012
- Exome sequencing identifies the cause of a mendelian disorderNature Genetics, 2009
- Mitochondrial Oxidative Phosphorylation Disorders Presenting in Neonates: Clinical Manifestations and Enzymatic and Molecular DiagnosesPediatrics, 2008
- Long-term Outcome and Clinical Spectrum of 73 Pediatric Patients With Mitochondrial DiseasesPediatrics, 2007
- Mitochondrial disease criteriaNeurology, 2006
- Recurrent de novo mitochondrial DNA mutations in respiratory chain deficiencyJournal of Medical Genetics, 2003